Kailera Therapeutics, Inc. Other Nonoperating Income (Expense)
Kailera Therapeutics, Inc. (KLRA) reported Other Nonoperating Income (Expense) of $72.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-12
- Kailera Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2026-06-30 was $72.00K.
- Kailera Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2026-03-31 was $5.79M, a 134.14% increase year-over-year.
- Kailera Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2025-06-30 was -$422.00K.
- Kailera Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2025-03-31 was $2.48M.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month |
|---|---|---|
| 2026-06-30 | $72.00K 10-Q · filed 2026-08-12 | $151.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $5.79M 10-Q · filed 2026-05-26 | |
| 2025-06-30 | -$422.00K 10-Q · filed 2026-08-12 | $377.00K 10-Q · filed 2026-08-12 |
| 2025-03-31 | $2.48M 10-Q · filed 2026-05-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |